NIKKEI 225
38,211.04 -63.01 (-0.16%) HANG SENG
18,205.50 +442.47 (+2.49%) CRUDE OIL
79.54 +0.54 (+0.68%) GOLD FUTURES
2,323.50 +12.50 (+0.54%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,873.92 -1,915.93 (-4.01%)
OCGN Jan 2025 1.500 call
| Previous close | 0.5700 |
| Open | 0.6400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.5500 - 0.6400 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal
ZacksOcugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
- GlobeNewswire
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial),
